Richard Pietras to Estrogen Receptor Modulators
This is a "connection" page, showing publications Richard Pietras has written about Estrogen Receptor Modulators.
Connection Strength
0.873
-
Hurvitz SA, Pietras RJ. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. 2008 Nov 01; 113(9):2385-97.
Score: 0.341
-
Dowsett M, Nicholson RI, Pietras RJ. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat. 2005; 93 Suppl 1:S11-8.
Score: 0.262
-
Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, M?rquez-Garb?n DC, Desai AJ, Dering J, Hosmer W, von Euw EM, Dubinett SM, Slamon DJ. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):270-8.
Score: 0.115
-
M?rquez-Garb?n DC, Chen HW, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann N Y Acad Sci. 2009 Feb; 1155:194-205.
Score: 0.087
-
Weinberg OK, Marquez-Garban DC, Pietras RJ. New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resist Updat. 2005 Aug; 8(4):219-33.
Score: 0.068